1 エグゼクティブ・サマリー
2 序文
2.1 概要
2.2 ステークホルダー
2.3 調査範囲
2.4 調査方法
2.4.1 データマイニング
2.4.2 データ分析
2.4.3 データの検証
2.4.4 リサーチアプローチ
2.5 リサーチソース
2.5.1 一次調査ソース
2.5.2 セカンダリーリサーチソース
2.5.3 前提条件
3 市場動向分析
3.1 はじめに
3.2 推進要因
3.3 抑制要因
3.4 機会
3.5 脅威
3.6 技術分析
3.7 エンドユーザー分析
3.8 新興市場
3.9 Covid-19の影響
4 ポーターズファイブフォース分析
4.1 供給者の交渉力
4.2 買い手の交渉力
4.3 代替品の脅威
4.4 新規参入の脅威
4.5 競争上のライバル関係
5 細胞・遺伝子治療CDMOの世界市場（治療タイプ別
5.1 はじめに
5.2 細胞療法
5.2.1 自己細胞療法
5.2.2 同種細胞療法
5.2.3 CAR-T細胞療法
5.3 遺伝子治療
5.3.1 In Vivo遺伝子治療
5.3.2 生体外遺伝子療法
5.4 その他の治療
6 細胞・遺伝子治療CDMOの世界市場（サービスタイプ別
6.1 導入
6.2 プロセス開発
6.3 製造
6.3.1 細胞培養
6.3.2 ベクター製造
6.3.3 精製
6.3.4 製剤化
6.4 分析サービス
6.5 品質保証および品質管理（QA/QC）
6.6 規制当局サポート
6.7 充填・仕上げ業務
7 細胞・遺伝子治療CDMOの世界市場、技術別
7.1 はじめに
7.2 ウイルスベクター
7.2.1 アデノウイルスベクター
7.2.2 レンチウイルスベクター
7.2.3 アデノ随伴ウイルスベクター
7.3 非ウイルス性方法
7.3.1 CRISPR/Cas9
7.3.2 トランスポゾン
7.3.3 プラスミドDNA
7.4 幹細胞技術
7.5 T細胞受容体
7.6 その他の技術
8 細胞・遺伝子治療CDMOの世界市場（エンドユーザー別
8.1 はじめに
8.2 バイオ医薬品企業
8.3 研究機関
8.4 学術機関
8.5 政府機関
8.6 バイオテクノロジー新興企業
9 細胞・遺伝子治療CDMOの世界市場、地域別
9.1 はじめに
9.2 北米
9.2.1 アメリカ
9.2.2 カナダ
9.2.3 メキシコ
9.3 ヨーロッパ
9.3.1 ドイツ
9.3.2 イギリス
9.3.3 イタリア
9.3.4 フランス
9.3.5 スペイン
9.3.6 その他のヨーロッパ
9.4 アジア太平洋
9.4.1 日本
9.4.2 中国
9.4.3 インド
9.4.4 オーストラリア
9.4.5 ニュージーランド
9.4.6 韓国
9.4.7 その他のアジア太平洋地域
9.5 南米
9.5.1 アルゼンチン
9.5.2 ブラジル
9.5.3 チリ
9.5.4 その他の南米地域
9.6 中東・アフリカ
9.6.1 サウジアラビア
9.6.2 アラブ首長国連邦
9.6.3 カタール
9.6.4 南アフリカ
9.6.5 その他の中東・アフリカ地域
10 主要開発
10.1 契約、パートナーシップ、提携、合弁事業
10.2 買収と合併
10.3 新製品上市
10.4 事業拡大
10.5 その他の主要戦略
11 会社プロファイル
Aldevron
Atara Biotherapeutics, Inc.
Bluebird Bio, Inc.
Bristol-Myers Squibb (Celgene)
Catalent, Inc.
Cytiva (part of GE Healthcare)
Fujifilm Diosynth Biotechnologies
Kite Pharma (a Gilead Company)
Lonza Group AG
NantKwest, Inc.
Novartis AG
Paragon Bioservices, Inc.
Pioneer BioTech
Precision BioSciences, Inc.
Regenative Labs
Roche
Sangamo Therapeutics, Inc.
Thermo Fisher Scientific Inc.
VivaCell Biotechnology and WuXi AppTec.
表一覧
表1 細胞・遺伝子治療CDMOの世界市場展望：地域別（2022-2030年） ($MN)
表2 細胞・遺伝子治療CDMOの世界市場展望：治療タイプ別（2022-2030年） ($MN)
表3 細胞・遺伝子治療CDMOの世界市場展望：細胞療法別 (2022-2030) ($MN)
表4 細胞・遺伝子治療CDMOの世界市場展望：自己細胞療法別（2022-2030年） ($MN)
表5 細胞・遺伝子治療CDMOの世界市場展望：同種細胞療法別 (2022-2030) ($MN)
表6 細胞・遺伝子治療CDMOの世界市場展望：CAR-T細胞療法別（2022-2030年） ($MN)
表7 細胞・遺伝子治療CDMOの世界市場展望：遺伝子治療別 (2022-2030) ($MN)
表8 細胞・遺伝子治療CDMOの世界市場展望：生体内遺伝子治療別 (2022-2030) ($MN)
表9 細胞・遺伝子治療CDMOの世界市場展望：生体外遺伝子治療別 (2022-2030) ($MN)
表10 細胞・遺伝子治療CDMOの世界市場展望：その他の治療タイプ別 (2022-2030) ($MN)
表11 細胞・遺伝子治療CDMOの世界市場展望：サービスタイプ別 (2022-2030) ($MN)
表12 細胞・遺伝子治療CDMOの世界市場展望：プロセス開発別 (2022-2030) ($MN)
表13 細胞・遺伝子治療CDMOの世界市場展望：製造別 (2022-2030) ($MN)
表14 細胞・遺伝子治療CDMOの世界市場展望：細胞培養別 (2022-2030) ($MN)
表15 細胞・遺伝子治療CDMOの世界市場展望：ベクター製造別 (2022-2030) ($MN)
表16 細胞・遺伝子治療CDMOの世界市場展望：精製別 (2022-2030) ($MN)
表17 細胞・遺伝子治療CDMOの世界市場展望：製剤別 (2022-2030) ($MN)
表18 細胞・遺伝子治療CDMOの世界市場展望：分析サービス別 (2022-2030) ($MN)
表19 細胞・遺伝子治療CDMOの世界市場展望：品質保証・品質管理（QA/QC）別 (2022-2030) ($MN)
表20 細胞・遺伝子治療CDMOの世界市場展望：薬事サポート別 (2022-2030) ($MN)
表21 細胞・遺伝子治療CDMOの世界市場展望：充填・仕上げ業務別 (2022-2030) ($MN)
表22 細胞・遺伝子治療CDMOの世界市場展望：技術別 (2022-2030) ($MN)
表23 細胞・遺伝子治療CDMOの世界市場展望：ウイルスベクター別 (2022-2030) ($MN)
表24 細胞・遺伝子治療CDMOの世界市場展望：アデノウイルスベクター別 (2022-2030) ($MN)
表25 細胞・遺伝子治療CDMOの世界市場展望：レンチウイルスベクター別 (2022-2030) ($MN)
表26 細胞・遺伝子治療CDMOの世界市場展望：アデノ随伴ウイルスベクター別 (2022-2030) ($MN)
表27 細胞・遺伝子治療CDMOの世界市場展望：非ウイルス法別 (2022-2030) ($MN)
表28 細胞・遺伝子治療CDMOの世界市場展望：CRISPR/Cas9別 (2022-2030) ($MN)
表29 細胞・遺伝子治療CDMOの世界市場展望：トランスポゾン別 (2022-2030) ($MN)
表30 細胞・遺伝子治療CDMOの世界市場展望：プラスミドDNA別 (2022-2030) ($MN)
表31 細胞・遺伝子治療CDMOの世界市場展望：幹細胞技術別 (2022-2030) ($MN)
表32 細胞・遺伝子治療CDMOの世界市場展望：T細胞受容体別 (2022-2030) ($MN)
表33 細胞・遺伝子治療CDMOの世界市場展望：その他の技術別 (2022-2030) ($MN)
表34 細胞・遺伝子治療CDMOの世界市場展望：エンドユーザー別 (2022-2030) ($MN)
表35 細胞・遺伝子治療CDMOの世界市場展望：生物製薬会社別 (2022-2030) ($MN)
表36 細胞・遺伝子治療CDMOの世界市場展望：研究機関別 (2022-2030) ($MN)
表37 細胞・遺伝子治療CDMOの世界市場展望：学術機関別 (2022-2030) ($MN)
表38 細胞・遺伝子治療CDMOの世界市場展望：政府機関別 (2022-2030) ($MN)
表39 細胞・遺伝子治療CDMOの世界市場展望：バイオテクノロジー新興企業別 (2022-2030) ($MN)
注：北米、ヨーロッパ、APAC、南米、中東・アフリカ地域の表も上記と同様に表記しています。
Market Dynamics:
Driver:
Increasing demand for cell and gene therapies
The increasing demand for cell and gene therapies in biotech companies focus on creating novel treatments for genetic disorders, cancers, and chronic diseases, they rely on CDMOs for expertise in complex processes like gene editing, viral vector production, and cell culture. CDMOs help meet the rising demand by offering scalable manufacturing, regulatory compliance, and faster time to market, enabling biotech firms to focus on research and innovation without the heavy investment in infrastructure, thereby accelerating the market's growth.
Restraint:
High costs and complex manufacturing processes
High costs and complex manufacturing processes requires highly specialized facilities and equipment, driving up operational costs. Additionally, the need for stringent quality control measures and personalized manufacturing processes further increases expenses. These factors can make it challenging for CDMOs to achieve economies of scale, limiting their profitability and hindering market growth. Consequently, the high costs associated with cell and gene therapy manufacturing can create barriers to entry for new players and limit the availability of these therapies to patients, hampering the market growth.
Opportunity:
Collaborations and partnerships
Collaborations and partnerships in Biopharma companies, academic institutions, and CDMOs work together to accelerate research, streamline clinical development, and scale manufacturing. These alliances enable faster innovation, cost-sharing, and risk mitigation, particularly in the complex and high-cost development of cell and gene therapies. By leveraging each partner's strengths, collaborations foster efficient technology transfer, regulatory support, and market entry, ultimately propelling the growth and success of the CDMO market.
Threat:
Regulatory and quality failures
The Cell and Gene Therapy CDMO Market is susceptible to several negative effects such as increased costs, reputational harm, delayed product development, restricted market access, and legal concerns due to regulatory and quality failures. CDMOs' capacity to draw in new business and partnerships may be hampered by non-compliance, which may result in penalties, recalls, and shutdowns. Moreover, poor quality might undermine CDMOs' credibility and shrink their prospective clientele thereby, hindering the market growth.
Covid-19 Impact
The COVID-19 pandemic has significantly impacted the Cell and Gene Therapy CDMO market by causing disruptions in supply chains, clinical trials, and regulatory processes. Many CDMOs faced delays in project timelines due to restrictions on laboratory access and workforce shortages. However, the pandemic also accelerated investments in bio manufacturing capabilities and the adoption of digital technologies, enhancing operational efficiency. The demand for rapid therapeutic responses to emerging health crises highlighted the importance of flexible and scalable CDMO services.
The cell therapy segment is expected to be the largest during the forecast period
The cell therapy segment is projected to account for the largest market share during the projection period, by offering groundbreaking treatments for conditions like cancer, autoimmune disorders, and degenerative diseases. Cell therapies, such as CAR-T and stem cell treatments, require highly specialized which many biotech companies outsource to CDMOs. The growing demand for personalized and regenerative medicine, coupled with the challenges of scaling production for clinical use, has led to increased reliance on CDMOs. This segment's rapid advancements and regulatory approvals further boost market growth.
The viral vectors segment is expected to have the highest CAGR during the forecast period
The viral vectors segment is projected to have the highest CAGR in the viral vectors market during the extrapolated period, due to their essential role in delivering therapeutic genes into target cells. As the demand for innovative gene therapies grows, viral vectors, such as adenoviruses, lentiviruses, and adeno-associated viruses, have become vital tools for effective gene transfer. CDMOs specializing in viral vector production provide essential services, including development, manufacturing, and quality control, which are crucial for clinical trials and commercialization. Additionally, advancements in vector design and production techniques enhance efficacy and safety, further driving demand and encouraging biopharmaceutical companies to collaborate with CDMOs for their expertise in this area.
Region with largest share:
The Asia Pacific region is projected to account for the largest market share during the forecast period due to increased investments in biotechnology, improving healthcare infrastructure, and rising demand for innovative therapies. Countries like China, Japan, and India are emerging as key players, benefiting from government initiatives promoting research and development. The region’s diverse patient population offers ample opportunities for personalized medicine, while local CDMOs are expanding their capabilities to cater to both domestic and international clients. Collaborations with global pharmaceutical companies further enhance the region's competitiveness in the cell and gene therapy landscape.
Region with highest CAGR:
During the estimation period, the North America region is forecasted to record the highest growth rate, owing to significant investments in research and development. The region boasts a robust infrastructure, advanced technologies, and a high concentration of biotechnology companies and academic institutions. Additionally, regulatory support from agencies like the FDA has accelerated the approval process for cell and gene therapies. The rising prevalence of genetic disorders further fuels demand for tailored therapies, positioning North America as a key player in this rapidly growing market.
Key players in the market
Some of the key players profiled in the Cell and Gene Therapy CDMO Market include Aldevron, Atara Biotherapeutics, Inc., Bluebird Bio, Inc., Bristol-Myers Squibb (Celgene), Catalent, Inc., Cytiva (part of GE Healthcare), Fujifilm Diosynth Biotechnologies, Kite Pharma (a Gilead Company), Lonza Group AG, NantKwest, Inc., Novartis AG, Paragon Bioservices, Inc., Pioneer BioTech, Precision BioSciences, Inc., Regenative Labs, Roche, Sangamo Therapeutics, Inc., Thermo Fisher Scientific Inc., VivaCell Biotechnology and WuXi AppTec.
Key Developments:
In October 2024, Lonza completed acquisition of large-scale Biologics site in Vacaville, one of the largest biologics manufacturing facilities in the world. Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network.
In September 2024, Lonza and Vertex signed a long-term commercial supply agreement for CASGEVY®. By this Vertex will leverage Lonza’s scientific, regulatory and manufacturing expertise, global manufacturing network, and Lonza will manufacture CASGEVY® at the state-of-the-art cGMP cell therapy manufacturing facilities, with plans to expand to its Portsmouth (US) facility.
In May 2024, Catalent and Siren Biotechnology entered into partnership a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies. This partnership demonstrates Catalent commitment to a robust manufacturing process that will move therapeutic programs into the clinic as quickly as possible.
Type of Therapies Covered:
• Cell Therapy
• Gene Therapy
• Other Type of Therapies
Service Types Covered:
• Process Development
• Manufacturing
• Analytical Services
• Quality Assurance and Quality Control (QA/QC)
• Regulatory Support
• Fill and Finish Operations
Technologies Covered:
• Viral Vectors
• Non-Viral Methods
• Stem Cell Technology
• T-cell Receptor
• Other Technologies
End Users Covered:
• Biopharmaceutical Companies
• Research Institutes
• Academic Institutions
• Government Organizations
• Biotechnology Start-ups
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cell and Gene Therapy CDMO Market, By Type of Therapy
5.1 Introduction
5.2 Cell Therapy
5.2.1 Autologous Cell Therapy
5.2.2 Allogeneic Cell Therapy
5.2.3 CAR-T Cell Therapy
5.3 Gene Therapy
5.3.1 In Vivo Gene Therapy
5.3.2 Ex Vivo Gene Therapy
5.4 Other Type of Therapies
6 Global Cell and Gene Therapy CDMO Market, By Service Type
6.1 Introduction
6.2 Process Development
6.3 Manufacturing
6.3.1 Cell Culture
6.3.2 Vector Manufacturing
6.3.3 Purification
6.3.4 Formulation
6.4 Analytical Services
6.5 Quality Assurance and Quality Control (QA/QC)
6.6 Regulatory Support
6.7 Fill and Finish Operations
7 Global Cell and Gene Therapy CDMO Market, By Technology
7.1 Introduction
7.2 Viral Vectors
7.2.1 Adenoviral Vectors
7.2.2 Lentiviral Vectors
7.2.3 Adeno-Associated Viral Vectors
7.3 Non-Viral Methods
7.3.1 CRISPR/Cas9
7.3.2 Transposons
7.3.3 Plasmid DNA
7.4 Stem Cell Technology
7.5 T-cell Receptor
7.6 Other Technologies
8 Global Cell and Gene Therapy CDMO Market, By End User
8.1 Introduction
8.2 Biopharmaceutical Companies
8.3 Research Institutes
8.4 Academic Institutions
8.5 Government Organizations
8.6 Biotechnology Start-ups
9 Global Cell and Gene Therapy CDMO Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Aldevron
11.2 Atara Biotherapeutics, Inc.
11.3 Bluebird Bio, Inc.
11.4 Bristol-Myers Squibb (Celgene)
11.5 Catalent, Inc.
11.6 Cytiva (part of GE Healthcare)
11.7 Fujifilm Diosynth Biotechnologies
11.8 Kite Pharma (a Gilead Company)
11.9 Lonza Group AG
11.10 NantKwest, Inc.
11.11 Novartis AG
11.12 Paragon Bioservices, Inc.
11.13 Pioneer BioTech
11.14 Precision BioSciences, Inc.
11.15 Regenative Labs
11.16 Roche
11.17 Sangamo Therapeutics, Inc.
11.18 Thermo Fisher Scientific Inc.
11.19 VivaCell Biotechnology
11.20 WuXi AppTec
List of Tables
Table 1 Global Cell and Gene Therapy CDMO Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Cell and Gene Therapy CDMO Market Outlook, By Type of Therapy (2022-2030) ($MN)
Table 3 Global Cell and Gene Therapy CDMO Market Outlook, By Cell Therapy (2022-2030) ($MN)
Table 4 Global Cell and Gene Therapy CDMO Market Outlook, By Autologous Cell Therapy (2022-2030) ($MN)
Table 5 Global Cell and Gene Therapy CDMO Market Outlook, By Allogeneic Cell Therapy (2022-2030) ($MN)
Table 6 Global Cell and Gene Therapy CDMO Market Outlook, By CAR-T Cell Therapy (2022-2030) ($MN)
Table 7 Global Cell and Gene Therapy CDMO Market Outlook, By Gene Therapy (2022-2030) ($MN)
Table 8 Global Cell and Gene Therapy CDMO Market Outlook, By In Vivo Gene Therapy (2022-2030) ($MN)
Table 9 Global Cell and Gene Therapy CDMO Market Outlook, By Ex Vivo Gene Therapy (2022-2030) ($MN)
Table 10 Global Cell and Gene Therapy CDMO Market Outlook, By Other Type of Therapies (2022-2030) ($MN)
Table 11 Global Cell and Gene Therapy CDMO Market Outlook, By Service Type (2022-2030) ($MN)
Table 12 Global Cell and Gene Therapy CDMO Market Outlook, By Process Development (2022-2030) ($MN)
Table 13 Global Cell and Gene Therapy CDMO Market Outlook, By Manufacturing (2022-2030) ($MN)
Table 14 Global Cell and Gene Therapy CDMO Market Outlook, By Cell Culture (2022-2030) ($MN)
Table 15 Global Cell and Gene Therapy CDMO Market Outlook, By Vector Manufacturing (2022-2030) ($MN)
Table 16 Global Cell and Gene Therapy CDMO Market Outlook, By Purification (2022-2030) ($MN)
Table 17 Global Cell and Gene Therapy CDMO Market Outlook, By Formulation (2022-2030) ($MN)
Table 18 Global Cell and Gene Therapy CDMO Market Outlook, By Analytical Services (2022-2030) ($MN)
Table 19 Global Cell and Gene Therapy CDMO Market Outlook, By Quality Assurance and Quality Control (QA/QC) (2022-2030) ($MN)
Table 20 Global Cell and Gene Therapy CDMO Market Outlook, By Regulatory Support (2022-2030) ($MN)
Table 21 Global Cell and Gene Therapy CDMO Market Outlook, By Fill and Finish Operations (2022-2030) ($MN)
Table 22 Global Cell and Gene Therapy CDMO Market Outlook, By Technology (2022-2030) ($MN)
Table 23 Global Cell and Gene Therapy CDMO Market Outlook, By Viral Vectors (2022-2030) ($MN)
Table 24 Global Cell and Gene Therapy CDMO Market Outlook, By Adenoviral Vectors (2022-2030) ($MN)
Table 25 Global Cell and Gene Therapy CDMO Market Outlook, By Lentiviral Vectors (2022-2030) ($MN)
Table 26 Global Cell and Gene Therapy CDMO Market Outlook, By Adeno-Associated Viral Vectors (2022-2030) ($MN)
Table 27 Global Cell and Gene Therapy CDMO Market Outlook, By Non-Viral Methods (2022-2030) ($MN)
Table 28 Global Cell and Gene Therapy CDMO Market Outlook, By CRISPR/Cas9 (2022-2030) ($MN)
Table 29 Global Cell and Gene Therapy CDMO Market Outlook, By Transposons (2022-2030) ($MN)
Table 30 Global Cell and Gene Therapy CDMO Market Outlook, By Plasmid DNA (2022-2030) ($MN)
Table 31 Global Cell and Gene Therapy CDMO Market Outlook, By Stem Cell Technology (2022-2030) ($MN)
Table 32 Global Cell and Gene Therapy CDMO Market Outlook, By T-cell Receptor (2022-2030) ($MN)
Table 33 Global Cell and Gene Therapy CDMO Market Outlook, By Other Technologies (2022-2030) ($MN)
Table 34 Global Cell and Gene Therapy CDMO Market Outlook, By End User (2022-2030) ($MN)
Table 35 Global Cell and Gene Therapy CDMO Market Outlook, By Biopharmaceutical Companies (2022-2030) ($MN)
Table 36 Global Cell and Gene Therapy CDMO Market Outlook, By Research Institutes (2022-2030) ($MN)
Table 37 Global Cell and Gene Therapy CDMO Market Outlook, By Academic Institutions (2022-2030) ($MN)
Table 38 Global Cell and Gene Therapy CDMO Market Outlook, By Government Organizations (2022-2030) ($MN)
Table 39 Global Cell and Gene Therapy CDMO Market Outlook, By Biotechnology Start-ups (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
